AP9901582A0 - Combination therapy for musculoskeletal frailty. - Google Patents

Combination therapy for musculoskeletal frailty.

Info

Publication number
AP9901582A0
AP9901582A0 APAP/P/1999/001582A AP9901582A AP9901582A0 AP 9901582 A0 AP9901582 A0 AP 9901582A0 AP 9901582 A AP9901582 A AP 9901582A AP 9901582 A0 AP9901582 A0 AP 9901582A0
Authority
AP
ARIPO
Prior art keywords
compositions
frailty
combination therapy
oxo
phenyl
Prior art date
Application number
APAP/P/1999/001582A
Other languages
English (en)
Inventor
Huazhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP9901582A0 publication Critical patent/AP9901582A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
APAP/P/1999/001582A 1998-06-16 1999-06-15 Combination therapy for musculoskeletal frailty. AP9901582A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
AP9901582A0 true AP9901582A0 (en) 1999-06-30

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001582A AP9901582A0 (en) 1998-06-16 1999-06-15 Combination therapy for musculoskeletal frailty.

Country Status (30)

Country Link
EP (1) EP1087764A1 (is)
JP (1) JP2002518326A (is)
KR (1) KR20010052852A (is)
CN (1) CN1301160A (is)
AP (1) AP9901582A0 (is)
AR (1) AR018869A1 (is)
AU (1) AU4054799A (is)
BG (1) BG105041A (is)
BR (1) BR9911324A (is)
CA (1) CA2335134A1 (is)
CO (1) CO5070587A1 (is)
EA (1) EA200001186A1 (is)
GT (1) GT199900087A (is)
HN (1) HN1999000097A (is)
HR (1) HRP20000859A2 (is)
HU (1) HUP0102505A3 (is)
ID (1) ID27599A (is)
IL (1) IL138630A0 (is)
IS (1) IS5691A (is)
MA (1) MA26652A1 (is)
NO (1) NO20006312D0 (is)
OA (1) OA11505A (is)
PA (1) PA8475901A1 (is)
PE (1) PE20000646A1 (is)
PL (1) PL344981A1 (is)
SK (1) SK18912000A3 (is)
TN (1) TNSN99124A1 (is)
TR (1) TR200003544T2 (is)
WO (1) WO1999065486A1 (is)
ZA (1) ZA993975B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047735A2 (en) * 1999-02-08 2000-08-17 Mcgill University NON-HUMAN TRANSGENIC ANIMAL WHOSE GERM CELLS AND SOMATIC CELLS CONTAIN A KNOCKOUT MUTATION IN DNA ENCODING ORPHAN NUCLEAR RECEPTOR ERRalpha
ES2274854T3 (es) 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
MXPA03001771A (es) * 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
HUP0102505A2 (hu) 2001-11-28
IL138630A0 (en) 2001-10-31
IS5691A (is) 2000-10-27
GT199900087A (es) 2000-12-07
JP2002518326A (ja) 2002-06-25
CN1301160A (zh) 2001-06-27
HUP0102505A3 (en) 2002-12-28
PL344981A1 (en) 2001-11-19
PA8475901A1 (es) 2000-05-24
BG105041A (en) 2001-08-31
PE20000646A1 (es) 2000-08-05
EA200001186A1 (ru) 2001-06-25
NO20006312L (no) 2000-12-12
CO5070587A1 (es) 2001-08-28
WO1999065486A1 (en) 1999-12-23
ID27599A (id) 2001-04-12
HN1999000097A (es) 1999-11-03
SK18912000A3 (sk) 2001-10-08
KR20010052852A (ko) 2001-06-25
TR200003544T2 (tr) 2001-04-20
AU4054799A (en) 2000-01-05
TNSN99124A1 (fr) 2005-11-10
NO20006312D0 (no) 2000-12-12
HRP20000859A2 (en) 2001-04-30
MA26652A1 (fr) 2004-12-20
OA11505A (en) 2004-05-07
AR018869A1 (es) 2001-12-12
ZA993975B (en) 2000-12-15
CA2335134A1 (en) 1999-12-23
BR9911324A (pt) 2001-04-03
EP1087764A1 (en) 2001-04-04

Similar Documents

Publication Publication Date Title
DE60037836D1 (de) ThiazoloÄ4,5-dÜpyrimidinverbindungen zur Behandlung von rheumathoider Arthritis
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
UA84146C2 (ru) Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
AP9901582A0 (en) Combination therapy for musculoskeletal frailty.
NO20001515L (no) Vitronektin reseptor-antagonist
AP9901580A0 (en) Therapeutic combination comprising a selective estrogen receptor modulator and parathyroid hormone.
AP9901581A0 (en) Therapeutic combinations for musculoskeletal frailty.
NZ330944A (en) Peptide derivatives
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
CA2274381A1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2